BiotechTube

ASP4070 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rhinitis, Allergic, Seasonal

Conditions

Rhinitis, Allergic, Seasonal

Trial Timeline

Apr 13, 2017 → Oct 27, 2018

NCT ID
NCT03101267

About ASP4070 + Placebo

ASP4070 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Rhinitis, Allergic, Seasonal. The current trial status is completed. This product is registered under clinical trial identifier NCT03101267. Target conditions include Rhinitis, Allergic, Seasonal.

What happened to similar drugs?

20 of 20 similar drugs in Rhinitis, Allergic, Seasonal were approved

Approved (20) Terminated (2) Active (0)
✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅BudesonideJohnson & JohnsonApproved
✅Cetirizine + LoratadineJohnson & JohnsonApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅Loratadine + BetamethasoneMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03101267Phase 2Completed
NCT02469688Phase 1Completed

Competing Products

20 competing products in Rhinitis, Allergic, Seasonal

See all competitors
ProductCompanyStageHype Score
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
35
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
29
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
DSP-3025 + PlaceboSumitomo PharmaPhase 1
29
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
ciclesonide HFA 160 μgSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
35